Wegovy Supply Issues and What to Do If Your Treatment Is Affected

Why Wegovy supply problems happen, and why they're hard to predict

The shortage isn't a mystery. When a medicine moves from specialist-clinic use to widespread private prescribing (and faces growing NHS demand on top) manufacturing simply can't always keep pace. Novo Nordisk has invested heavily in production, but the fill-and-finish process for injectable biologics takes months, and a disruption anywhere in the chain ripples forward. The result is that particular strengths (often the mid-range doses patients titrate through most predictably) can disappear from UK wholesalers for weeks at a time.

One misconception worth setting aside: some people assume a reputable online pharmacy will always have stock somewhere, even when others don't. In reality, all UK pharmacies source through the same licensed supply chain, no legitimate pharmacy has a secret warehouse that the shortage doesn't touch. If the authorised distributor doesn't have a dose, nobody does. What varies between providers is transparency: a good pharmacy tells you straight rather than quietly backordering for weeks.

The position changes month to month. NHS England's guidance on weight management injections acknowledges supply variability and the importance of clinical support when it occurs. That support matters most precisely when stock is unreliable.

What a supply gap actually means for your treatment plan

The clinical stakes of an interruption depend on where you are in your titration. Missing a week or two while established on your maintenance dose is generally less disruptive than a gap mid-titration, where you may need to re-escalate more slowly. Your prescriber should be the person who decides that, not forum advice, not a pharmacist's best guess at the counter.

If your usual dose strength is unavailable, three things can happen: your pharmacy sources it as soon as it comes back in, your prescriber considers whether staying on a lower available strength temporarily is appropriate, or an alternative licensed medicine is discussed. Tirzepatide (Mounjaro), the only dual GIP and GLP-1 receptor agonist licensed for weight management in the UK, is one option some patients move to following a prescriber review. You can read more about how the two medicines compare on the semaglutide overview page or the broader weight management options page.

The thing to avoid is pausing treatment entirely without a plan, or sourcing a pen from an unverified seller. The MHRA has documented serious harms from counterfeit weight-loss pens sold online and through social media, including pens containing insulin rather than semaglutide.

How to make the right call for your situation

This is the decision the page is really about. You're not choosing between a good option and a bad one; you're weighing imperfect paths, and the right one depends on your dose, how long you've been on treatment, your weight-loss progress, and any conditions your prescriber is managing alongside.

A few practical questions worth working through with a clinician. How long has the shortage lasted for your specific strength? A two-week wait is very different from a six-week gap with no confirmed restock date. Is staying on a lower available dose clinically reasonable for you? Is this a moment to discuss whether tirzepatide might suit you better long-term? If you've been managing well on Wegovy and want to understand your one-month supply situation specifically, that page goes into the stock picture in more detail.

The broader context of Wegovy's UK supply position is covered separately if you want the wider picture before deciding, and if you're planning ahead, our Wegovy three-month supply page explains what ordering in advance looks like and whether it's currently available. For patients already thinking about other difficulties they've encountered beyond stock, the common issues with Wegovy page covers side effects and other clinical concerns, and you can also find a dedicated overview of semaglutide issues if you want to understand problems that apply across semaglutide-based treatments more broadly.

At nume, our clinical team reviews every repeat order individually, not by algorithm. That means supply gaps don't just create a logistics problem; they prompt a genuine clinical conversation about what to do next, specific to you. If you're weighing up your options, you can check your eligibility for a consultation and speak to a prescriber the same day.